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Abstract5
Traditional coronary drug-eluting stents (DES) are made from metal and are coated with
a permanent polymer film containing an anti-proliferative drug. Subsequent to stent de-
ployment in a diseased coronary artery, the drug releases into the artery wall and helps
prevent restenosis by inhibiting the proliferation of smooth muscle cells. Although this
technology has proven to be remarkably successful, there are ongoing concerns that
the presence of a polymer in the artery can lead to deleterious medical complications,
such as late stent thrombosis. Polymer-free DES may help overcome such shortcom-
ings. However, the absence of a rate-controlling polymer layer makes optimisation of
the drug release profile a particular challenge. The use of microporous stent surfaces
to modulate the drug release rate is an approach that has recently shown particularly
promising clinical results. In this study, we develop a mathematical model to describe
drug release from such stents. In particular, we develop a mathematical model to de-
scribe drug release from microporous surfaces. The model predicts a two-stage release
profile, with a relatively rapid initial release of most of the drug, followed by a slower
release of the remaining drug. In the model, the slow release phase is accounted for by
an adsorption/desorption mechanism close to the stent surface. The theoretical predic-
tions are compared with experimental release data obtained in our laboratory, and good
agreement is found. The valuable insights provided by our model will serve as a useful
guide for designing the enhanced polymer-free stents of the future.
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model, atomic force microscopy7
1. Introduction8
1.1. Background9
Coronary Heart Disease (CHD) remains the leading cause of death globally, being re-10
sponsible for around 16% of all deaths annually in high-income countries [1]. Although11
medical treatments can be used to manage the symptoms in the early stages of the12
disease, more advanced cases ultimately require revascularisation of the affected vascu-13
lature to reduce the risk of myocardial infarction and heart failure. Despite the fact that14
coronary artery bypass graft revascularisation procedures are still commonly performed,15
with some evidence of better long-term outcomes for patients with multi-vessel disease16
and/or existing co-morbidities [2, 3], the majority of coronary revascularisations are now17
performed by percutaneous coronary intervention (PCI).18
In PCI, a balloon-mounted stent is expanded into the artery wall to restore blood19
flow through the affected lesion [4]. Following withdrawal of the balloon, the stent20
provides permanent mechanical support to the vessel wall. Although the use of bare21
metal stents (BMS) represented a significant improvement on balloon angioplasty alone,22
BMS suffered from relatively high rates of in-stent restenosis (ISR) [5] due, at least in23
part, to excessive smooth muscle cell (SMC) proliferation within the vascular wall [6].24
It was found that local release of anti-proliferative drugs from the stent surface could25
inhibit this proliferative response, with the first two drug-eluting stents (DES) [7, 8]26
achieving quite dramatic reductions in ISR. However, these early generation devices27
were also associated with late-stent thrombosis [9, 10, 11]. Although the precise causes28
of late-stent thrombosis remain to be determined, discontinuation of dual anti-platelet29
therapy has been associated with its occurrence, indicating incomplete restoration of30
a functional endothelium [9]. Further evidence in support of this came from post-31
mortem and angiographic investigations that demonstrated that complete recovery of32
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the endothelium was much more rapidly achieved in those patients who had been treated33
with a bare metal stent, compared to a first generation DES [10, 12]. Such findings34
provided the stimulus for the development of alternative DES, making use of alternative35
drugs and coating technologies [13]. There has since been a trend towards the use of36
analogues of sirolimus, with the latest devices increasingly using either biodegradable37
or polymer-free drug coatings to provide sustained release of the drug.38
Stents featuring biodegradable polymer coatings [16, 17] include the Biomatrix Stent39
(Biosensors International), the DESyne BD NOVOLIMUS Stent (Elixir Medical Copo-40
ration), the Nobori Stent (Terumo), the COMBO Dual Therapy Stent (OrbusNeich),41
and the Supralimus-Core Stent (SMT). In recent years, companies have also been pur-42
suing the development of fully bioresorbable stents [18, 19], examples of these being43
provided by the Absorb Stent (Abbott Vascular), the DESolve Stent (Elixir Medical44
Coporation), and the SYNERGY Bioabsorbable Stent (Boston Scientific).45
Polymer-free stents abandon the use of a polymeric drug carrier altogether and in-46
stead employ technologies that are usually (though not always) based on directly cov-47
ering a bare surface of the stent strut with drug [20, 21]. This surface may be relatively48
smooth, as in the case of the Amazonia Pax Stent (MINVASYS), or may be specially49
modified to receive the drug and modulate its subsequent release rate. In the latter50
case, microporous surface technology is the most commonly used in the manufacture51
of currently available polymer-free stents. A microporous surface contains pits whose52
breadth, depth and separation are on the order of micrometres in scale, and the Yukon53
(Translumina Therapeutics), Yinyi (Yinyi Biotech), Vestasync (MIV Therapeutics) and54
Biofreedom (Biosensors International) stents are all examples of devices that employ55
this technology; see Figure 1 and Figure 2. Some nanoporous systems for drug delivery56
from stents have also been investigated [22, 23].57
The mathematical modelling of drug delivery in general [24, 25], and drug delivery in58
3
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Figure 1: Images of three drug-eluting stents that employ microporous surface technology. (a) Reprinted
from [14] with permission from Yinyi Biotech. An image of a portion of the surface of a Yinyi stent
strut. The surface contains pores whose diameters are between 1 and 2 µm and whose depths are less
than 500 nm. The surface is coated with the drug Paclitaxel. (b) Reprinted from [15] with permission
from Translumina. Images of the Yukon Choice PC stent. The surface of the Yukon stent contains of
the order of 1 million pores per cm2, and the average depth of the pores is approximately 2 µm. (c)
Reprinted from [16] with permission from the American Heart Association. An image of a portion of
the surface of a BioFreedom stent strut. The abluminal surface of the strut is microstructured and is
loaded with the drug Biolimus A9.
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the context of DES in particular [26, 27, 28], has received considerable attention in the59
literature in recent decades. Mathematical modelling provides a potentially powerful60
tool in the analysis and design of drug delivery systems. Such models can help opti-61
mise the design of a particular drug delivery system by guiding what device geometry,62
composition and drug-loading should be selected to achieve a desired release profile.63
This in turn can lead to a reduction in the number of experiments required for product64
development, with consequent savings in time and expense. More fundamentally, it is65
sometimes not even clear what the dominant drug delivery mechanisms in a particu-66
lar system are, and mathematical modelling in conjunction with experimental data can67
assist in identifying these.68
To our knowledge, there are no existing modelling studies that focus on drug release69
from microporous stent surfaces. However, there does exist some limited modelling stud-70
ies on nanoporous surfaces that are of relevance. Gultepe et al. [29] developed a model71
to describe drug release from a nanotubular metallic surface. Although they charac-72
terised their systems as being nanotubular, they did consider drug-filled tubes that had73
diameters as large as 0.2 µm. They assumed that the drug release was due to a desorp-74
tion process in which the drug molecules have to overcome an activation energy barrier75
before leaving the surface. The activation energy was assumed to depend quadratically76
on the surface coverage of drug, and the resulting model produced results that matched77
their experimental data. In a more recent study, Tzur-Balter et al. [30] developed a78
diffusion-based mathematical model to describe drug release from an eroding porous79
silicon surface. However, the pore diameters considered in their study were significantly80
smaller than a micrometre. Finally, our group have recently reported on the develop-81
ment of mathematical models for nanoporous, nanotubular and smooth surface systems82
[31]. In the current study, we develop mathematical models to describe drug release83
from microporous surfaces. In [31], we consider drug diffusion through nanoporous and84
5
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nanotubular systems, and these are bulk phenomena that require the consideration of85
material porosities. However, in the current study, we model drug release from a mi-86
croporous surface, and the novel features of the behaviour here are surface-dominated.87
The emphasis here will be on DES, although our results may also be applicable more88
generally to any drug delivery device that employs microporous technology to modulate89
the drug release rate.90
1.2. Outline91
In this paper, we provide a model to describe the elution of drug from microporous92
DES. We start by describing the typical drug release experiment that we wish to model.93
We then formulate a system of one-dimensional coupled reaction-diffusion equations de-94
scribing the drug release and demonstrate that these reduce to a single diffusion equation95
with a spatially varying diffusion coefficient, after making some reasonable assumptions.96
The release of drug is in two parts: a fast release phase for the bulk of the drug followed97
by a slow release phase for drug located close to the surface. Starting with the assump-98
tion of an unstirred release medium and no medium replacement at measurements, we99
are able to derive an analytical solution for the first phase of release. Subsequent release100
when the surface region has been exposed is solved for numerically. For the case of an101
unstirred release medium with medium replacement at each measurement, we derive an102
analytical solution for the release profile for both phases of the release. This solution103
is compared with our in vitro experimental data of drug release from the Yukon stent.104
The model is shown to capture the release profile well, and moreover we show how it is105
possible to inversely estimate unknown parameters in the system. Remarkably we are106
able to demonstrate mathematically that if the switchover point between the initial fast107
release and slow release phases can be determined from the experimental release profile,108
then the first phase of the release is determined solely from the coordinates of this point.109
Finally, we provide a mathematical model for the well-stirred case.110
6
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We stress that the models presented here are for drug release in an in vitro environ-111
ment: such in vitro testing is an important part of early-stage DES design since it helps112
to give an indication of the release profiles that can be obtained from a prototype stent113
platform as well as verifying the repeatability of the drug release profiles.114
2. Experimental methods115
2.1. Characterisation of stent surface topography116
Atomic Force Microscopy (AFM) (MFP 3D, Asylum Research, CA, USA) was used117
to characterise the surface features of three uncoated stainless steel Yukon Choice 4 (3118
× 8 mm) stents. A small sample from each stent, consisting of a limited number of119
struts, was cut free from the expanded stent and adhered onto a glass slide. AFM scans120
were then performed in intermittent contact mode in air, imaging four random points121
on each stent surface. All scans were performed at a frequency of 1 Hz with scan sizes122
ranging from 1 - 20 µm. Representative images obtained are shown in Figure 2, from123
which we observe that the depth, breadth and separation of the surface pits are of the124
order of micrometres in scale. Sirolimus coated Yukon stents, on the other hand, have125
previously been shown to be markedly smoother than their bare metal equivalents [32].126
2.2. In vitro drug release experiments127
The surface of a Yukon Choice stent (3 × 16 mm) was coated once using a solution128
of rapamycin (10 mg/ml) in ethanol. The Translumina dose-adjustable coating machine129
was used to apply the coating according to the manufacturer’s instructions. The drug130
coated stent was placed in a glass vial containing 2 ml of release medium (phosphate131
buffered saline:ethanol (90:10)). The stent was then removed to a separate glass vial132
containing fresh release medium at each of the following time points: 10 min, 1, 2,133
6 hrs, 1, 3, 7, 14 and 28 days. The drug-containing release medium from each time134
point was stored at −20◦C prior to further analysis. All experiments were performed135
7
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(a)
(b)
Figure 2: Atomic force microscopy images of the surface of the Yukon Choice stent. Images are
representative of three separate stent surfaces, each imaged at four randomly selected locations, at
a scan size of (a) 5 µm and (b) 20 µm. Left hand panels are 2D orthographic projections with the
corresponding 3D image shown on the right hand panels. The depth, breadth and separation of the
surface pits are of the order of micrometres in scale.
in unstirred release media maintained at 37◦C. The samples collected were analysed136
using UV-spectroscopy, with the peak absorbance measured at a wavelength of 279137
nm being used to estimate the rapamycin release from the stent surface. At the end138
of the release experiment, the stent was transferred to a glass vial and stored at -139
20◦C. In order to determine if any rapamycin was left on the stent after the 28 day140
incubation period, it was brought to room temperature and then immersed in 2 ml of141
cold methanol overnight. The rapamycin in the methanol solution was then analysed by142
UV spectroscopy as previously described. There was no residual rapamycin detected in143
the methanol solution, indicating that complete release of the initial drug mass coated144
on to the stent (193 µg) had occurred within the 28 day release period.145
8
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3. The mathematical model146
3.1. Preamble147
In Figure 3 (a), we schematically depict a layer of drug covering a microporous sur-148
face. The surface contains pits whose depth, diameter and separation are of the order of149
micrometres in size. The system is placed in a release medium and the drug dissolves.150
Throughout this paper, we shall assume that the drug dissolves from its exposed surface151
only and that fluid does not penetrate the drug interior. For systems in which there is152
significant fluid ingress into the drug bulk, effects such as fragmentation may be signif-153
icant and the analysis presented here may not then be appropriate. However, it should154
be noted that the classical dissolution models do not take account of fragmentation155
[33, 34, 35], although there are some studies that do incorporate the effect [36].156
A typical drug molecule has dimensions on the order of nanometres, and this is three157
orders of magnitude smaller than the typical dimensions of the microporous pits. Hence158
surface roughness on the scale of micrometres will not in general significantly affect159
the dissolution behaviour of individual drug molecules. However, surface roughness on160
submicron scales (see Figure 3 (a)) can have a significant effect - for example, on a161
lengthscale of nanometres, there may be van der Waals interactions between the drug162
molecules and the surface. A surface that is rough on a number of different lengthscales163
may have a relatively large surface area, so that a significant proportion of the drug164
loaded may be influenced by short-range surface effects. These effects will be incorpo-165
rated into the modelling of the current study.166
3.2. The unstirred case167
Based on the images of the stent surface obtained (see Figure 2), we consider a168
microporous surface as shown in Figure 3 (a). The surface is covered with drug and169
placed in an unstirred release medium. In Figure 3 (a), we have indicated the location170
of the mean plane of surface roughness for the microporous surface. For the purposes171
9
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Figure 3: (a) A microporous surface is covered with solid drug. The surface contains pits whose
depth, diameter and separation are on the order of micrometres in size. The mean plane of the surface
roughness is indicated on the figure. The blow-up shows that the surface is also rough on a submicron
scale, and the surface region indicated refers to the narrow region close to the surface where the effects
of adsorption and desorption can be significant. (b) To make the problem mathematically tractable,
we replace the microporous rough surface by the mean plane. However, we do include a surface region
in the modelling where adsorption to and desorption from the surface can be important effects. The
system is placed in a release medium, and the solid drug begins to dissolve. A moving boundary x = s(t)
separates the undissolved drug from the release medium. In the system as depicted, the surface region
is not yet exposed so that adsorption/desorption cannot occur. (c) At this stage of the release, the
surface region is exposed, and adsorption/desorption become significant effects.
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of formulating a useable mathematical model, we replace the microporous surface by172
the mean plane. We suppose that the mean plane is located at x = 0 and that uniform173
solid drug now occupies the region above the plane. At first sight, this might seem174
a crude assumption. However, for the scenarios we are envisaging here, it does have175
justification since the dissolution of most of the drug in the microporous pits (see Figure176
3 (a)) is unaffected by the surface; recall that the pits have dimensions on the order of177
micrometres, whereas the range of influence of the surface is on the order of nanometres.178
This aligns well with the observed biphasic release profile shown in Figure 6 (b).179
When the system is placed in a release medium, it dissolves from its exposed surface,180
and a moving boundary x = s(t) separates the undissolved drug from the release medium181
as shown in Figure 3 (b). The surface region is defined to be the neighbourhood of x = 0182
where adsorption to and desorption from the surface are non-negligible effects, and we183
take this to occupy 0 < x < a. Figure 3 (b) depicts the system at a stage when the184
drug still covers the surface region, so that surface effects do not enter. However, once185
the surface region has been exposed, adsorption/desorption become significant effects186
(Figure 3 (c)).187
We shall develop a mathematical model that tracks the evolution of two distinct188
species of drug: free drug dissolved in the release medium and bound drug adhering to189
the rough surface. We denote by b(x, t) and c(x, t) the concentrations of bound drug190
and free drug, respectively, at location x and time t. The concentrations for b and c can191
only change in the region x > s(t), and so we need only display equations for this region.192
Since the release medium is taken to be unstirred here, diffusion is the only transport193
mechanism in the bulk of the fluid, and we have194
∂c
∂t
= Dw
∂2c
∂x2
− ka(x)c+ kd(x)b, x > s(t), t > 0, (1)
∂b
∂t
= ka(x)c− kd(x)b, x > s(t), t > 0, (2)
11
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where195
ka(x) =


ka if 0 < x < a,
0 if x > a,
kd(x) =


kd if 0 < x < a,
0 if x > a,
(3)
and where Dw, ka and kd are constants. Here Dw is the diffusion coefficient for the196
free drug, and ka and kd are parameters characterising the rate of drug adsorption197
and desorption, respectively. The forms chosen for ka(x) and kd(x) in (3) ensure that198
drug adsorption and desorption are restricted to the surface region only. It should be199
emphasised here that b(x, t) = 0 for all x > a, t > 0.200
It is noteworthy in (1) and (2) that we have not taken the adsorption rate ka(x)c to201
be dependent on the concentration of binding sites. This assumption is valid when the202
concentration of available binding sites greatly exceeds the concentration of adsorbate203
molecules so that the concentration of binding sites may be taken to be constant. How-204
ever, models have previously been proposed that do track the concentration of binding205
sites; see, for example, the Langmuir model [37] for the adsorption of gaseous molecules206
to a solid surface.207
Adding (1) to (2) gives208
∂
∂t
(c+ b) = Dw
∂2c
∂x2
, x > s(t), t > 0, (4)
an equation describing the evolution of the total drug concentration. For x > s(t) > a,209
we have ∂b/∂t = 0, so that210
∂c
∂t
= Dw
∂2c
∂x2
, x > s(t) > a, t > 0. (5)
For s(t) < x < a, we have211
∂b
∂t
= kac− kdb, s(t) < x < a, t > 0. (6)
12
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We assume here that the adsorption/desorption processes equilibriate on a time scale212
that is short compared to the other time scales arising in the system, so that (6) can be213
replaced by214
b(x, t) = kac(x, t)/kd, s(t) < x < a, t > 0. (7)
Substituting (7) in (4) now gives215
∂c
∂t
= De
∂2c
∂x2
, s(t) < x < a, t > 0, (8)
where216
De =
Dw
1 + 1/Kd
< Dw, (9)
and where Kd = kd/ka. Combining (5) and (8) gives217
∂c
∂t
=
∂
∂x
(
D(x)
∂c
∂x
)
, x > s(t), t > 0, (10)
where218
D(x) =


De (< Dw) if 0 < x < a,
Dw if x > a.
(11)
Equation (10) is an appealing result since it implies that the effect of the rough surface219
on the drug release rate may be incorporated in a position-dependent drug diffusion220
coefficient. Away from the surface, diffusion is ‘fast’ with D(x) = Dw, but in the221
neighbourhood of the surface, diffusion is ‘slow’ with D(x) = De < Dw.222
We now supplement (10) with boundary and initial conditions appropriate to the223
case of an unstirred release medium. We denote by cs the solubility of the free drug in224
the release medium. The solubility is the maximum possible concentration of dissolved225
drug in the release medium, and at the interface between the undissolved drug and the226
13
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medium, we suppose that c is at solubility, so that227
c = cs on x = s(t), t > 0. (12)
Sufficiently far into the release medium, the concentration of drug falls to zero, so that228
c→ 0 as x→∞, t > 0. (13)
Notice that we have taken the release medium to be infinite in extent here. This is229
a reasonable assumption if the release medium has a representative lengthscale on the230
order of centimetres, which is the case for the experiments conducted for the current231
study. We suppose that at t = 0, the drug layer occupies 0 < x < Ld and that the initial232
concentration of undissolved drug is c0. We then have the following initial conditions:233
s(t = 0) = Ld, c(x, t = 0) = 0 for x > Ld, c(x, t = 0) = c0 for 0 < x < Ld. (14)
To obtain a well-posed problem, we need another boundary condition to determine the234
motion of x = s(t), the moving dissolution front. This will be derived by invoking235
conservation of drug. For s(t) > a, the total amount of drug in the system is given by236
m(t) = A
{∫
a
0
(1 + ka/kd)c0 dx+
∫
s(t)
a
c0 dx+
∫ ∞
s(t)
c dx
}
.
where A is the cross-sectional area of the drug-covered plane. Imposing dm(t)/dt = 0237
for s(t) > a now gives238
0 =
dm(t)
dt
= A
{
c0
ds
dt
− csds
dt
+
∫ ∞
s(t)
Dw
∂2c
∂x2
dx
}
= A
{
(c0 − cs)ds
dt
−
(
Dw
∂c
∂x
)
x=s(t)
}
14
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so that239
−Dw ∂c
∂x
=
ds
dt
(cs − c0) on x = s(t), s(t) > a. (15)
A similar calculation for s(t) < a gives that240
−De ∂c
∂x
=
ds
dt
(cs − c0) on x = s(t), s(t) < a. (16)
Combining (15) and (16) now yields241
−D(x) ∂c
∂x
=
ds
dt
(cs − c0) on x = s(t), t > 0. (17)
Combining the equations formulated above now provides the following well-posed initial242
boundary value problem for the free drug c:243
∂c
∂t
=
∂
∂x
(
D(x)
∂c
∂x
)
, x > s(t), t > 0,
c = cs, −D(x) ∂c
∂x
=
ds
dt
(cs − c0) on x = s(t), t > 0, (18)
c→ 0 as x→∞, t > 0,
s(t = 0) = Ld, c(x, t = 0) = 0 for x > Ld.
We shall discuss solutions to this problem in Section 4.244
3.3. A well-stirred release medium245
The formulation for the well-stirred case is very different from that for the unstirred246
case. When the medium is well-stirred, a boundary layer of poorly stirred fluid forms247
close to the surface of the dissolving drug layer ([33],[38]). This layer is taken here to be248
of thickness h; the size of h depends on the degree of agitation in the fluid bulk. We shall249
take the release medium to be finite in extent and to initially occupy Ld < x < Lw +Ld250
where Ld and Lw give the initial thicknesses of the drug and release medium, respectively.251
15
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Figure 4: In the case of a well-stirred release medium, a narrow boundary layer of poorly stirred fluid
forms near the surface of the solid drug. The location of the pure drug surface is denoted by x = s(t),
and the system is depicted here at some time t > 0. It is assumed that the flux of drug from the
dissolving surface is proportional to the difference between the drug concentration at the surface and
the drug concentration in the well-stirred release medium. This schematic is not drawn to scale.
A moving boundary x = s(t), initially located at x = Ld, separates the release medium252
from the pure drug layer. We assume here that h≪ Ld ≪ Lw and denote by cu(t) the253
spatially uniform drug concentration in the well-stirred medium at time t. In Figure 4,254
we schematically depict the various regions and associated drug concentrations.255
We assume here that the flux of drug from the surface of the dissolving drug layer is256
proportional to the difference between the concentration of drug in the release medium257
and the concentration of drug at the surface. Denoting by j|x=s(t) the flux of drug from258
x = s(t), we write259
j|x=s(t) = −D(s(t))(cu(t)− cs)
h
(19)
where cs is the drug concentration on x = s(t), and D(s) is the position dependent260
diffusivity of the drug in the release medium as defined by (11). Equation (19) can be261
regarded as a statement of Fick’s first law of diffusion at x = s(t). In view of (17), the262
16
Page 18 of 37
Ac
ce
pte
d M
an
us
cri
pt
appropriate equation for the speed of the front is now263
−D(s)(cu(t)− cs)
h
=
ds
dt
(cs − c0) for t > 0. (20)
Equating the amount of drug that has dissolved with the amount in the release medium264
and using the assumptions that h≪ Ld ≪ Lw and cu(t)≪ c0, we have265
(Ld − s(t))c0 ≈ Lwcu(t). (21)
Combining (20) and (21) leads to the following initial value problem for s(t):266
ds
dt
+
D(s)
hLw
c0
c0 − cs s ≈
D(s)
hLw
Ldc0 − Lwcs
c0 − cs , t > 0, (22)
s = Ld at t = 0.
We shall discuss the solution to this problem in Section 4.267
3.4. Release profiles268
We begin by considering the unstirred case. For the purposes of the current study,269
we define the total amount of drug released by the system at any time t to be the total270
amount of drug in solution in the release medium at this time. Denoting this quantity271
by M(t), we have that272
M(t) = A
∫ ∞
s(t)
c(x, t)dx,
where, recall, A is the cross-sectional area of the drug-covered plane. If we assume that273
s(t) > a, then274
dM(t)
dt
= A
(∫ ∞
s(t)
∂c
∂t
dx− ds(t)
dt
c(s(t)+, t)
)
= A
([
Dw
∂c
∂x
]∞
x=s(t)+
− ds(t)
dt
cs
)
,
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and if we now employ the second boundary condition in the second line of the equation275
list (18), we arrive at276
dM(t)
dt
= −Ac0ds(t)
dt
. (23)
A similar calculation shows that (23) also holds for 0 < s(t) < a. Integrating (23)277
subject to M(0) = 0, s(0) = Ld gives278
M(t) = Ac0(Ld − s(t)).
All of the drug has dissolved by time t = td where td is determined from s(td) = 0, and279
at this time, M(td) = Ac0Ld. Assuming that the boundary x = 0 is impermeable to280
drug, it is easily shown that dM(t)/dt = 0 for t > td, so that M(td) = M(∞) = Ac0Ld.281
A release profile is a plot of the fraction of the total drug that has released as a function282
of time t, and it is given here by283
M(t)
M(∞) =


1− s(t)/Ld for 0 ≤ t < td,
1 for t ≥ td.
(24)
A similar analysis shows that the formula for the release profile for the well-stirred case284
is also given by (24).285
4. Results and discussion286
4.1. The unstirred problem287
We now consider the solution to the problem (18). For s(t) > a, the problem can be288
solved explicitly, and the details of the solution method can be found in McGinty et al.289
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[31]. For s(t) > a, the solution is given by290
s(t) = Ld − θ
√
t, c = cs
erfc
(
x−Ld
2
√
Dwt
)
erfc
(
− θ
2
√
Dw
) , Ld − θ√t < x <∞, (25)
where θ is determined by solving the nonlinear equation291
θ
2
√
Dw
exp
(
θ2
4Dw
)
erfc
(
− θ
2
√
Dw
)
=
1√
pi
cs
c0 − cs . (26)
This solution remains valid until t = ta where s(ta) = a, so that292
ta =
(Ld − a)2
θ2
.
For t > ta, the governing equations are:293
∂c
∂t
=
∂
∂x
(
D(x)
∂c
∂x
)
, x > s(t), t > ta,
c = cs, −De ∂c
∂x
=
ds
dt
(cs − c0) on x = s(t), t > ta, (27)
c→ 0 as x→∞, t > ta,
s(t = ta) = a, c(x, t = ta) = cs
erfc
(
x−Ld
2
√
Dwta
)
erfc
(
− θ
2
√
Dw
) for x > a,
where θ is determined from (26). This problem cannot be solved analytically, and so294
we employed a front-tracking numerical scheme to obtain approximate solutions. The295
details of the scheme can be found in Appendix A. The transition between the rapid296
and the slow release can be identified on the release profile shown in Figure 6 (a) and297
occurs at the point298
(ta,M(ta)/M(∞)) =
(
(Ld − a)2/θ2, 1− a/Ld
)
. (28)
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Equation (28) is of value when assessing experimental data. If in an experimental release299
profile the transition point is clearly identifiable, then comparing the experimental result300
with the theoretical prediction (28) should enable the estimation of the parameters a301
and θ if Ld is known. Explicitly, a may be estimated using the formula302
a = Ld
(
1− M(ta)
M(∞)
)
(29)
and then303
θ =
Ld − a√
ta
. (30)
Equation (26) can now be used to provide an estimate for the free drug diffusion coef-304
ficient Dw if cs/c0 is known. Conversely, if Dw is known, (26) provides an estimate for305
cs/c0, which in turn can provide an estimate for the drug solubility cs if c0 is known.306
Remarkably, it transpires that the first phase of the release profile is determined
solely from the coordinates of this transition point. To see this, we combine (24) and
(25) to obtain
M(t)
M(∞) = 1−
s(t)
Ld
=
θ
√
t
Ld
for 0 ≤ t < ta,
from which we deduce that307
M(t)
M(∞) =
M(ta)
M(∞)
√
t
ta
for 0 ≤ t < ta. (31)
The significance of this last result is that, if we can identify the transition point on the308
experimental release profile, then this is all the information we need to simulate the first309
phase of the release.310
4.1.1. Numerical solutions311
In Figure 5, we display theoretically generated drug release profiles for the unstirred312
case where the release medium is not replaced. The curves were calculated using the313
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Figure 5: Theoretically generated drug release profiles for the unstirred case without medium replace-
ment. The curves were calculated using (24) and (25) and by numerically integrating (27). Here Dw
is the diffusion coefficient of the drug in the release medium, De is the effective diffusion coefficient of
the drug in the surface region, Ld is the initial thickness of the drug layer, a is the thickness of the
surface region, c0 is the initial concentration of the undissolved dry drug, and cs is the solubility of
the drug in the release medium. Unless stated otherwise on the figure, the parameter values used are
Dw = 5 × 10−7 cm2s−1, De/Dw = 10−6, Ld = 10 µm, a/Ld = 0.2, and c0/cs = 50. In the plots,
we display drug release profiles for (a) varying values of the effective drug diffusion coefficient in the
surface region, (b) varying values of the solubility, and (c) varying thicknesses of the surface region.
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formulae (24) and (25) and by numerically integrating (27) and illustrate the quite wide314
variety of release behaviours the system is capable of exhibiting. Figure 5 (a) shows the315
effect of varying the effective drug diffusion coefficient De in the surface region, and the316
results are as expected with the release rate in the slow phase decreasing with decreasing317
De. The effective diffusion coefficient depends on the adsorption/desorption properties318
of the drug molecules with the surface.319
The effect of varying the drug solubility cs is shown in Figure 5 (b). The behaviour320
here is seen to be strongly dependent on the solubility in the early rapid stage of the321
release (see the inset), with the curves exhibiting a quite dramatic slowing in the drug322
release rate with decreasing cs. This behaviour can be understood by noting that for323
cs/c0 ≪ 1, we have from (26) that θ ≈ 2
√
Dw/pi cs/c0, so that324
ta ≈ (Ld − a)2 pi
4Dw
(
c0
cs
)2
,
implying that the duration of the rapid release phase depends on the square of the325
inverse of the drug solubility. This remark is consistent with the behaviour exhibited in326
the inset of Figure 5 (b).327
In Figure 5 (c), we display release curves for various thicknesses of the surface region.328
For these curves, the initial stages of the profiles are identical because the surface plays329
no role in the release behaviour here. In designing a real system, changing a would330
correspond to changing the roughness characteristics of the surface. However, it should331
be stated that in the current study, no explicit connection has been made between the332
parameters appearing in the mathematical model and surface roughness parameters333
[39]. Nevertheless, we can conclude that from the point of view of delaying the release334
of a larger fraction of the drug, roughness on both micron and submicron scales is335
preferable to roughness on submicron scales alone since the total surface area in the336
former case is larger. Larger surface areas imply that a larger fraction of the drug load337
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is initially adhering to the surface, and this fraction releases more slowly. In terms of338
our modelling, larger surface areas correspond to larger values of the effective surface339
thickness parameter a.340
4.1.2. Implications for choice of drug to be coated on microporous stents341
Whilst biphasic kinetics are clearly a feature of these microporous stents, it is evident342
from Figure 5 that the majority of the drug is released rapidly. Indeed, for the wide343
range of parameters that we have simulated, most of the drug is released within the344
first day. In order to evaluate the potential clinical significance of this finding, we must345
assess these rapid release profiles in the context of restenosis development, a process346
that occurs over a period of weeks after stent implantation.347
We note that the drugs coated on early DES included heparin, paclitaxel and sirolimus.348
Early mathematical modelling (for example [40]) helped explain the failure of hydrophilic349
heparin stents and the relative success of paclitaxel and sirolimus eluting stents, based350
on analysis of their partitioning and transport properties in arterial tissue. In particu-351
lar, sirolimus and paclitaxel are extremely poorly soluble hydrophobic compounds that352
bind tenaciously to the arterial wall. Sirolimus is an anti-proliferative compound that353
targets the FK-binding protein 12 (FKBP12) [41]. This complex subsequently binds to354
the mammalian target of rapamycin (mTOR) and thereby interrupts the cell cycle in355
the G1-S phase. Paclitaxel is also an anti-proliferative compound; however, it inhibits356
neointimal growth by binding with and stabilising microtubules, resulting in cell-cycle357
arrest in the G0-G1 and G2-M phases [42].358
Recently, mathematical modelling has been used to help explain how differences in359
the binding properties of sirolimus and paclitaxel lead to different drug persistence times360
in the wall, suggesting that the optimal delivery strategy is drug dependent [43]. For361
example, whilst the timescale for binding of sirolimus (∼ 5 minutes) is much quicker362
than for paclitaxel (∼ 5 hours), the timescale for unbinding of sirolimus (∼ 11 hours)363
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is considerably shorter than that of paclitaxel (∼ 210 hours). Based on time scale364
analysis, Bozsak et al. [43] postulated that paclitaxel-eluting stents perform optimally by365
releasing their drug either very rapidly (within a few hours) or very slowly (over periods366
of several months) [43], and in contrast, sirolimus-eluting stents perform optimally only367
when drug release is slow [43]. The implication is that for the Yukon Choice stent368
studied here, coating with paclitaxel or a drug with similar binding properties may369
actually be preferable in terms of combatting restenosis. Alternatively, strategies to370
slow the sirolimus release may be advantageous, and we note that the manufacturer of371
the stent under study is actively pursuing such approaches. Since the current state-of-372
the-art indicates that receptor saturation is strongly linked with efficacy [26], we further373
note that it may, in principle, be possible to design a microporous stent where the rate374
of the second phase of release is tuned to match declining receptor saturation levels,375
thereby acting to replenish the drug in the tissue and prolonging receptor saturation.376
4.1.3. Unstirred, replaced release medium377
The situation we have described above assumes that the release medium is not378
changed between measurements. However, it is also common for the stent to be re-379
moved and placed in a fresh release medium between measurements. This strategy is380
typically adopted where there are constraints on the limit of detection of the drug. It381
is therefore of interest also to consider the case where the release medium is replaced.382
Mathematically this is modelled by a resetting of the drug concentration to zero in the383
release medium at every measurement time point. Assuming that the transition time ta384
between the fast release phase and the slow release phase corresponds to one of the mea-385
surement time points, the release profile can be computed using the following expression386
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(see Appendix B for details):387
M(t)
M(∞) =


θ
√
t
Ld
for 0 ≤ t < t1,
θ
Ld
(√
t1 +
√
t− t1
)
for t1 ≤ t < t2,
...
θ
Ld
(√
t1 +
√
t2 − t1 + . . .+
√
t− tn−1
)
for tn−1 ≤ t < tn,
1− a
Ld
+
θ∗
Ld
√
t− tn for tn ≤ t < td,
1 for t ≥ td,
(32)
where ti, i = 1, ..., n− 1 are the experimental time points before the transition, tn = ta388
is the time of the transition and td = tn + a
2/θ∗2 is the time by which all of the drug389
has dissolved. In (32), θ and θ∗ are both constant parameters, where θ is determined390
by solving (26) and θ∗ is determined by solving (see Appendix B)391
θ∗
2
√
Dw
exp
(
θ∗2
4De
)(
1−
√
Dw
De
erf
(
− θ
∗
2
√
De
))
=
1√
pi
cs
c0 − cs . (33)
Once again, provided that Ld is known, a and θ can be estimated from the experimental392
data point (ta,M(ta)/M(∞)). We can again estimate a using (29), and then393
θ =
Ld − a√
t1 +
√
t2 − t1 + . . .+√tn − tn−1
. (34)
We can now estimate Dw using (26) if cs/c0 is known or vice-versa.394
4.1.4. Comparison with experimental data395
In Figure 6, we display the results of the release experiment described in Section396
2.2. Figure 6 (b) shows the measured drug release profile plotted against the square397
root of time. The release profile is clearly biphasic, i.e. there is a clear transition point398
separating a fast initial rate of release from a subsequent slower rate of release. A simple399
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single phase dissolution model [31] is incapable of replicating such behaviour.400
In Figure 6 (a), we compare the theoretical profile (32) with the experimentally401
measured release profile plotted as a function of time. In order to use the formula402
(32), values for the parameters θ/Ld, a/Ld, θ
∗/Ld and tn = ta must be selected that403
are consistent with (34), and values were chosen here to obtain a good fit with the404
experimental data. The values selected can be found in the caption of Figure 6. It is405
noteworthy that it is not necessary to explicitly choose values for Dw, ka, kd, c0 and cs406
to implement the fitting. However, these values will satisfy the constraints (26) and407
(33) and so may be deducible indirectly depending on which parameters are known408
for a particular system. The reverse question is also worth considering - what system409
parameters need to be known in advance in order to apply the model directly to a410
particular system without fitting? Inspecting equations (26), (32), (33) and (34), it is411
seen that it is sufficient to specify values for Dw, De, cs/c0, Ld and a to implement the412
model.413
The biphasic character of the release in Figure 6 (a) is clear, with a relatively rapid414
initial release of most of the drug, followed by a slower release of the remaining drug.415
The theory developed in this paper posits that the fast release here corresponds to416
dissolution of drug away from the surface region, while the slow release corresponds417
to drug dissolution in the surface region. It is clear that our mathematical model is418
capturing the experimentally observed release profile well.419
4.2. The well-stirred problem420
To obtain the solution for the well-stirred case, we must solve the initial-value prob-421
lem (22). The solution to (22) for s(t) > a is given by422
s(t) = Ld − cs
c0
Lw
(
1− exp
(
− Dw
hLw
c0
(c0 − cs)t
))
. (35)
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Figure 6: (a) Comparison between experimental drug release data and the theoretical drug release
profile (32). The solid curve shown is theoretical, and the parameter values used to generate it are
a/Ld = 0.225, θ/Ld = 1.475, θ
∗/Ld = 0.078 and ta = 0.086 days. The diamonds give the experimental
release data, and the inset highlights the release behaviour over the first day of release. (b) Plot of the
experimental release data versus the square root of time.
This solution remains valid until t = ta where s(ta) = a. Using (35), we find that423
ta = −hLw
Dw
(c0 − cs)
c0
ln
(
1− c0
cs
(Ld − a)
Lw
)
. (36)
We remark that this quantity is only defined for 1 − c0(Ld − a)/csLw > 0, or csLw >424
c0(Ld−a). This corresponds to our intuitive expectations here since if csLw < c0(Ld−a),425
the release medium would become fully saturated with drug before s(t) could reach a,426
and dissolution would then cease.427
For t > ta, the motion of the moving boundary is governed by428
ds
dt
+
De
hLw
c0
c0 − cs s =
De
hLw
Ldc0 − Lwcs
c0 − cs , t > ta, (37)
s = a at t = ta,
and this has the solution429
s(t) =
(
Ld − cs
c0
Lw
)
−
(
Ld − cs
c0
Lw − a
)
exp
(
− De
hLw
c0
(c0 − cs)(t− ta)
)
(38)
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for t > ta. The time for all of the drug to dissolve, t = td, is determined by solving430
s(td) = 0. Using (38), this gives431
td = ta +
hLw
De
(c0 − cs)
c0
ln
(
1 +
a
csLw/c0 − Ld
)
.
Clearly for this to be physically meaningful we require that td > ta, which implies that432
csLw/c0 − Ld > 0 or csLw > c0Ld. This last condition implies that in order for td to be433
defined, the release medium must be capable of accommodating all of the drug before434
saturating. Finally for t > td, we clearly have s(t) = 0.435
Combining the results above and using (24), we now have that436
M(t)
M(∞) =


csLw
c0Ld
(
1− exp
(
− Dw
hLw
c0
(c0−cs)t
))
for 0 ≤ t < ta,
csLw
c0Ld
+
(
1− csLw
c0Ld
− a
Ld
)
exp
(
− De
hLw
c0
(c0−cs)(t− ta)
)
for ta ≤ t < td,
1 for t ≥ td.
(39)
5. Conclusions437
Microporous drug release systems have surfaces that are rough on the micron scale;438
that is, the breadth, depth and separation of the surface pits have dimensions of the439
order of microns. However, the molecular dimensions of drug molecules are typically440
of the order of nanometres, three orders of magnitude smaller than the dimensions of441
the pits. Hence, for solid drug that dissolves from its surface interface with the release442
medium only, the dissolution behaviour of most of the drug molecules in the pits may443
not be significantly affected by the presence of the surface. Hence, the concept that444
roughness on the scale of the micron can in and of itself significantly retard the release445
of a substantial fraction of the drug may not be valid for some systems. However,446
roughness on submicron scales can significantly retard drug release via surface effects447
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such as Van der Waals interactions; these forces act over a much shorter range than a448
micron. Nevertheless, such forces can still affect a significant amount of drug for systems449
whose surfaces are rough on both the micron and submicron scales since the total surface450
area can then be large. These observations motivated the development of the biphasic451
mathematical model presented in the current study.452
The mathematical model developed here is, to the best of our knowledge, the first453
that attempts to model drug release from microporous surfaces. Although our model454
does incorporate a number of significant simplifying assumptions to enable analytical455
progress, it does successfully capture the key features of the experimentally observed456
release behaviour. We conducted drug release experiments for a Yukon stent coated457
with rapamycin and found that the release profile had a distinct two-stage character,458
with most of the drug releasing relatively rapidly over a period of about half a day, and459
the remainder of the drug releasing more slowly over a period of about a week. This460
biphasic character of the experimental release is captured very well by our theoretical461
model. In our theoretical formulation, the slow release phase is accounted for by an462
effective diffusion coefficient for the drug in the neighbourhood of the surface that is463
smaller than the free drug diffusion coefficient.464
Simulations of the mathematical model indicate that microporous systems are ca-465
pable of exhibiting quite a broad range of release behaviours. Amongst the parameters466
that may be used to tune the character of release profiles are the thickness of the drug467
layer and, of course, the surface roughness. Moreover, and more interestingly, we note468
that experimental release data in conjunction with theoretical profiles can be used to469
estimate key system parameters, such as the free drug diffusion coefficient.470
Finally, we believe that it is appropriate to acknowledge that a number of assump-471
tions have been made in this analysis. Firstly, we replace the actual microporous surface472
by a mean plane representation, with our justification being that the dissolution of most473
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of the drug in the microporous pits is unaffected by the surface. Secondly, we have as-474
sumed that the drug dissolves from its exposed surface only. Thirdly, we have not taken475
the drug absorption rate on the stent surface to be dependent on the concentration of476
binding sites, an assumption which is valid when the concentration of available binding477
sites greatly exceeds the concentration of absorbate molecules. In deriving our analyt-478
ical solutions, we have assumed that the release medium is infinite in extent, which is479
a reasonable assumption when the length scale of the release medium is much greater480
than the diffusion length. Finally, the mathematical model presented does not account481
for the possibility of drug degradation in the release medium. A model which accounts482
simultaneously for drug release and degradation of drug is beyond the scope of this483
study and calls for the development of more sophisticated modelling approaches, which484
we will pursue in future work.485
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Appendix A. The numerical front-tracking scheme492
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